Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FTC blockage of Amgen's US$28 BLN takeover of Horizon

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 30, 2023 5:39pm

176 Views

Post# 35471188

RE:RE:RE:RE:RE:RE:FTC blockage of Amgen's US$28 BLN takeover of Horizon

May 25, 2023 - The timing here is critical for Amgen and its Big Pharma peers who face a wave of patent cliffs in coming years that will require M&A to make up for lost revenue. Between $200 billion to $300 billion is at risk before 2026 due to blockbuster biologics losing their market exclusivity, according to EY estimates.

“It couldn’t come at a worst time,” Ural said. “We have been forewarning about this looming massive biologics patent cliff — and you need to make up for that revenue to be able to afford more R&D.”

For the pharma industry, M&A isn’t just about consolidation, Ural argued — it’s the lifeblood of an extremely technical and fragmented area of innovation.

“What Big Pharma does best is take an asset that is hopefully scientifically sound and put it through late-stage clinical trials, which require a lot of capital and operational savvy,” Ural said. “We’re not designing sneakers or designer bags — you bring innovation in-house through acquisitions.”

https://www.pharmavoice.com/news/amgen-ftc-horizon-scotus-repatha-innovation/651202/

May 17, 2023 - "Thawing of interest in mega-deals would invariably shift consolidation focus to smaller and earlier-stage biotech companies – and more of them," Evercore analysts said in a note.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages